Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Mar 7:28:100286.
doi: 10.1016/j.ahjo.2023.100286. eCollection 2023 Apr.

Prescribing patterns of SGLT-2 inhibitors for patients with heart failure: A two-center analysis

Teja Chakrala  1 , Roshni O Prakash  1 , Justin Kim  1 , Hanzhi Gao  2 , Umar Ghaffar  3 , Jaymin Patel  3 , Alex Parker  4 , Bhagwan Dass  3
Affiliations

Prescribing patterns of SGLT-2 inhibitors for patients with heart failure: A two-center analysis

Teja Chakrala et al. Am Heart J Plus. .

Abstract

Background: Sodium glucose co-transporter 2 inhibitors (SGLT2i) have been proven to reduce the combined risk of cardiovascular death and hospitalizations in patients with heart failure (HF), irrespective of the presence or absence of diabetes. Despite class 1 and class 2A recommendations for their usage in HF with reduced ejection fraction (HFrEF) and HF with preserved ejection fraction (HFpEF) respectively by the American College of Cardiology, their prescription rate has remained low.

Objective: The aim of this study is to analyze SGLT2i prescription patterns at two academic institutions, with the goal of identifying barriers to implementation.

Design: A two-center retrospective analysis was conducted on patients ≥18 years old with a diagnosis of heart failure who were admitted to one of two hospital systems between 5/1/21 and 5/31/22. Patients with an eGFR ≥20 mL/min/1.73m2 and BNP ≥ 100 pg/mL were included.

Results: SGLT2i was prescribed in only 19 out of 1081 HFpEF patients (1.8 %) and 51 out of 1596 HFrEF patients (3.2 %). A majority of SGLT2i prescriptions for the HFpEF population came from general medicine services (57.9 %) after obtaining approval from a cardiologist, which was required at our institutions. Adverse effects such as hypoglycemia and urinary tract infections were not significantly associated with SGLT2i use.

Conclusions: Despite proven benefits of this class of medications as witnessed in large-scale clinical trials, the implementation of this drug class continues to be low.

Keywords: Heart failure; Heart failure with preserved ejection fraction; Prescribing patterns; Sodium-glucose cotransporter-2 inhibitors (SGLT-2i).

PubMed Disclaimer

Conflict of interest statement

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Figures

Fig. 1
Fig. 1
Depiction of services admitting heart failure hospitalizations.
See this image and copyright information in PMC

Similar articles

See all similar articles

References

    1. Rao S. Use of sodium-glucose cotransporter-2 inhibitors in clinical practice for heart failure prevention and treatment: beyond type 2 diabetes. A narrative review. Adv Ther. 2022;39(2):845–861. doi: 10.1007/s12325-021-01989-z. - DOI - PMC - PubMed
    1. Packer M., Anker S.D., Butler J., et al. Cardiovascular and renal outcomes with empagliflozin in heart failure. N. Engl. J. Med. 2020;383(15):1413–1424. doi: 10.1056/NEJMoa2022190. - DOI - PubMed
    1. Jackson S.L., Tong X., King R.J., Loustalot F., Hong Y., Ritchey M.D. National Burden of heart failure events in the United States, 2006 to 2014. Circ. Heart Fail. 2018;11(12) doi: 10.1161/CIRCHEARTFAILURE.117.004873. - DOI - PMC - PubMed
    1. Faridi K.F., Dayoub E.J., Ross J.S., et al. Medicare coverage and out-of-pocket costs of quadruple drug therapy for heart failure. J. Am. Coll. Cardiol. 2022;79(25):2516–2525. doi: 10.1016/j.jacc.2022.04.031. - DOI - PubMed
    1. Lytvyn Y., Bjornstad P., Udell J.A., Lovshin J.A., Cherney D.Z.I. Sodium glucose cotransporter-2 inhibition in heart failure: potential mechanisms, clinical applications, and summary of clinical trials. Circulation. 2017;136(17):1643–1658. doi: 10.1161/CIRCULATIONAHA.117.030012. - DOI - PMC - PubMed